Clinical Trials Directory
We are doing this study to find out if an experimental drug called cema-cel is a safe and effective option for patients with large B-cell lymphoma. Cema-cel is a CAR T Cell therapy that is made from your own white blood cells. We also want to compare how well cema-cel works when it is given with and without another experimental drug called ALLO-647.
In this study, people will get a medicine called CLSP-1025 through a needle in their arm. They may need to stay in the hospital for 2 days after the first two doses. They will have regular checkups, tests, and scans. The study can last up to 2 years if the medicine helps and they feel okay. Everyone in the study gets the medicine - no one gets a fake treatment.
We are doing this study to find out if neratinib combined with palbociclib is better than neratinib alone when it comes to treating HER2-positive tumors.
The study wants to learn three things: 1. How many patients with medulloblastoma can live at least 4 months without their tumor getting worse. 2. How many patients with DIPG live for 1 year after getting radiation and the PEP-CMV vaccine. 3. How many patients with HGG live for 1 year without their tumor getting worse after radiation and the PEP-CMV vaccine.
People in this study will visit the research center two times each month to see the study doctor. The study can last up to 2 years. Treatment happens in cycles, and each cycle is 28 days long, which is about 4 weeks. A person can have up to 26 cycles, which equals about 2 years of treatment. The amount of medicine given will depend on the person’s weight, which is checked before each new cycle. The medicine is called tocilizumab. It blocks a protein called interleukin-6, which causes swelling in the body. This medicine is usually used for diseases where the immune system attacks the body, like arthritis, and it can also help with a problem called cytokine release syndrome after certain cancer treatments.
We are doing this study to learn how to best support young women making decisions about breast cancer surgery. We want to know what makes women feel uncertain about their decision-making so we can become better at providing the information they need. This study involves testing a web-based decision support tool that is designed to help young women with newly diagnosed breast cancer with their surgical decisions.
We are doing this study to find out if an experimental drug called Actinium-225 rosopatamab tetraxetan (the study drug) is a safe and effective option for patients with castration-resistant prostate cancer (CRPC).
We are doing this study to find out if using ice with or without compression during chemotherapy can prevent neuropathy for patients being treated for gynecologic cancer.